HC Wainwright & Co. Maintains Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has maintained a Buy rating on Silence Therapeutics (NASDAQ:SLN) and kept the price target at $75.
March 13, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Silence Therapeutics with a $75 price target, indicating a positive outlook on the stock.
The maintenance of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. suggests a strong belief in the future performance of Silence Therapeutics. This endorsement could positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100